Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.

ABSTRACT:

Rationale

There is no consensus as to when treatment for idiopathic pulmonary fibrosis (IPF) should be initiated. Some physicians prefer not to treat patients with preserved lung volume.

Objective

To investigate whether patients with IPF and preserved lung volume receive the same benefit from nintedanib as patients with more impaired lung volume.

Methods

Post hoc subgroup analyses of pooled data from the two replicate phase III INPULSIS trials by baseline FVC % predicted (≤90%, >90%).

Results

At baseline, 274 patients had FVC >90% predicted and 787 patients had FVC ≤90% predicted. In patients treated with placebo, the adjusted annual rate of decline in FVC was consistent between patients with FVC >90% predicted and FVC ≤90% predicted (-224.6 mL/year and -223.6 

SUBMITTER: Kolb M 

PROVIDER: S-EPMC5520269 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature